Windtree Therapeutics (WINT)
OTHER OTC:WINT
Want to see WINT full AI Analyst Report?
WINT Stock Chart & Stats
$0.03
-$0.02(-5.33%)
At close: 4:00 PM EST
$0.03
-$0.02(-5.33%)
Day’s Range― - ―
52-Week Range<$0.01 - $1.86
Previous CloseN/A
Volume14.98M
Average Volume (3M)403.29K
Market Cap
$539.34K
Enterprise Value$13.21M
Total Cash (Recent Filing)$204.00K
Total Debt (Recent Filing)$12.93M
Price to Earnings (P/E)―
Beta1.28
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding33,708,782
10 Day Avg. Volume496,404
30 Day Avg. Volume403,289
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.09
Price to Sales (P/S)0.00
P/FCF Ratio-0.06
Enterprise Value/Market Cap24.49
Enterprise Value/Revenue146.73
Enterprise Value/Gross Profit1.20K
Enterprise Value/Ebitda-0.31
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Critical-care Biotech PipelineSpecialization in critical‑care and cardiopulmonary therapeutics is a durable strategic position: these are high‑unmet‑need areas with structural demand and limited crowded competition. A successful clinical advance could produce outsized long‑term returns relative to company size.
Ability To Access Capital For Strategic DealsIssuing senior convertible notes to fund an acquisition demonstrates the company can secure external financing and pursue M&A even with weak operations. Access to transactional capital supports strategic flexibility and potential inorganic growth over the medium term.
Lean Operating StructureA very small workforce indicates a lean cost base and focused R&D organization, which can extend runway per dollar of funding and enable nimble program management. For an early‑stage biotech, low overhead helps preserve capital for clinical priorities.
Bears Say
Negative Equity And Rising LeverageNegative equity and increased debt signal materially impaired balance‑sheet resilience. With equity deficit and higher leverage, the company faces elevated insolvency, refinancing and dilution risks, reducing financial flexibility to fund clinical programs long term.
Persistent, Sizable Cash BurnSustained negative operating and free cash flow of roughly -$15M TTM indicates ongoing dependence on external financing. Continuous cash burn threatens program continuity and increases the probability of dilutive financings or project delays over the next several quarters.
Recent Sudden Executive DepartureAn abrupt exit of the President/COO creates strategic and execution risk at a sensitive time for an R&D‑centric company. Leadership turnover can delay decision making, complicate fundraising and partnerships, and reduce continuity in clinical program execution.
Windtree Therapeutics News
WINT FAQ
What was Windtree Therapeutics’s price range in the past 12 months?
Windtree Therapeutics lowest stock price was <$0.01 and its highest was $1.86 in the past 12 months.
What is Windtree Therapeutics’s market cap?
Windtree Therapeutics’s market cap is $539.34K.
When is Windtree Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Windtree Therapeutics’s earnings last quarter?
Currently, no data Available
Is Windtree Therapeutics overvalued?
According to Wall Street analysts Windtree Therapeutics’s price is currently Overvalued.
Does Windtree Therapeutics pay dividends?
Windtree Therapeutics does not currently pay dividends.
What is Windtree Therapeutics’s EPS estimate?
Windtree Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Windtree Therapeutics have?
Windtree Therapeutics has 33,708,782 shares outstanding.
What happened to Windtree Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Windtree Therapeutics?
Currently, no hedge funds are holding shares in WINT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Windtree Therapeutics
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical firm primarily dedicated to developing therapies for acute cardiovascular ailments, and secondarily for acute pulmonary diseases. Its prominent therapeutic programs include istaroxime, undergoing Phase IIb clinical trials for acute decompensated heart failure and Phase IIa for early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant in Phase IIb for respiratory distress syndrome in preterm infants; Lyophilized KL4 surfactant, in Phase IIa trials for lung injury stemming from COVID-19; and Rostafuroxin, in Phase IIb for genetically associated hypertension. The company maintains collaborations, including one with Universita degli Studi di Milano-Bicocca for the discovery and advancement of novel SERCA2a compounds targeting chronic and acute human heart failure. It also holds a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and commercialization of a portfolio of potential KL4 surfactant products, and a collaboration with Battelle Memorial Institute to further develop its ADS for its Phase III program. Established in 1992 as Discovery Laboratories, Inc., the company rebranded as Windtree Therapeutics, Inc. in April 2016. It is headquartered in Warrington, Pennsylvania, and operates as a subsidiary of Lee's Pharmaceutical Holdings Limited.
Technical Analysis
Theriva Biologics
―
Indaptus Therapeutics
―
Enveric Biosciences
―
Artelo Biosciences
―
Azitra Inc
―